J
João T. Barata
Researcher at Instituto de Medicina Molecular
Publications - 99
Citations - 4619
João T. Barata is an academic researcher from Instituto de Medicina Molecular. The author has contributed to research in topics: Leukemia & T cell. The author has an hindex of 36, co-authored 86 publications receiving 3956 citations. Previous affiliations of João T. Barata include University of Lisbon & Harvard University.
Papers
More filters
Journal ArticleDOI
Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors
Ana Batista,João T. Barata,Elke Raderschall,Stephen E. Sallan,Nadia Carlesso,Lee M. Nadler,Angelo A. Cardoso,Angelo A. Cardoso +7 more
TL;DR: In this article, the authors evaluated the impact of rapamycin (mTOR) on T-cell acute lymphoblastic leukemia (T-ALL) and whether mTOR blockade synergizes with chemotherapeutic agents or other signaling antagonists to inhibit primary leukemia T cells.
Journal ArticleDOI
Expression and Subcellular Localization of a Novel Nuclear Acetylcholinesterase Protein
Susana Constantino Rosa Santos,Inês Sofia Vala,Cláudia Miguel,João T. Barata,Pedro Garção,Paula Agostinho,Marta Mendes,Ana Varela Coelho,Angelo Calado,Catarina R. Oliveira,João Martins e Silva,Carlota Saldanha +11 more
TL;DR: The studies suggest that the 55-kDa AChE may be involved in different biological processes such as neural development, tumor progression, and angiogenesis.
Journal ArticleDOI
A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.
Padma Akkapeddi,Rita Fragoso,Julie A. Hixon,Ana Sofia Ramalho,Mariana L. Oliveira,Tânia Carvalho,Andreas Gloger,Mattia Matasci,Francisco Corzana,Scott K. Durum,Dario Neri,Gonçalo J. L. Bernardes,Gonçalo J. L. Bernardes,João T. Barata +13 more
TL;DR: A B12–MMAE antibody–drug conjugate is engineered and proof-of-concept evidence that it has increased leukemia cell killing abilities as compared with the naked antibody is provided.
Journal ArticleDOI
Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor
Leila R. Martins,Yasser Perera,Paulo Lúcio,Maria Gomes da Silva,Silvio E. Perea,João T. Barata +5 more
TL;DR: It is shown that CIGB-300 promotes activation of the tumor suppressor PTEN and abrogates PI3K-mediated downstream signaling in CLL cells, and provides pre-clinical support for the testing and possible inclusion of CK2 inhibitors in the clinical arsenal against CLL.
Journal ArticleDOI
Molecular and functional evidence for activity of murine IL-7 on human lymphocytes.
TL;DR: It is demonstrated that mIL-7 affects human lymphocytes and indicates that mouse models of human lymphoid development and disease must integrate the biological effects of endogenous IL-7 on human cells.